Momenta acquires Virdante's sialic switch in potential $51 million deal
This article was originally published in Scrip
Executive Summary
Momenta Pharmaceuticals has made an upfront payment of $4.5 million to acquire the "sialic switch" assets of the US privately held biotech start-up, Virdante Pharmaceuticals, and says that it will make additional contingent milestone payments totalling $51.5 million. Momenta and Virdante are both based in Cambridge, Massachusetts.